A PYMNTS Company

US: Teva faces new competition after FDA okays MSgeneric

By  |  October 4, 2017

Mylan NV’s long-awaited US approval for its generic version of rival Teva’s blockbuster multiple sclerosis treatment (MS) Copaxone drove the drugmaker’s shares up more than 19% on Wednesday, October 4, morning and hurt Teva shares.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The approval late on Tuesday, October 2, by the US Food and Drug Administration came earlier than both companies had expected. It was issued a day after the health regulator said it would introduce a slew of measures to speed to market generic versions of complex drugs like Copaxone in an effort to address the rising cost of pharmaceuticals.

    Copaxone is the leading MS therapy worldwide as well as Teva’s best selling drug. It generated more than US$4 billion in revenue for the Israeli drugmaker last year.

    Full Content: Financial Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.